<code id='7BD71FD6E6'></code><style id='7BD71FD6E6'></style>
      • <acronym id='7BD71FD6E6'></acronym>
      <center id='7BD71FD6E6'><center id='7BD71FD6E6'><tfoot id='7BD71FD6E6'></tfoot></center><abbr id='7BD71FD6E6'><dir id='7BD71FD6E6'><tfoot id='7BD71FD6E6'></tfoot><noframes id='7BD71FD6E6'>
      • <optgroup id='7BD71FD6E6'><strike id='7BD71FD6E6'><sup id='7BD71FD6E6'></sup></strike><code id='7BD71FD6E6'></code></optgroup>
        5. <b id='7BD71FD6E6'><label id='7BD71FD6E6'><select id='7BD71FD6E6'><dt id='7BD71FD6E6'><span id='7BD71FD6E6'></span></dt></select></label></b><u id='7BD71FD6E6'></u>
          <i id='7BD71FD6E6'><strike id='7BD71FD6E6'><tt id='7BD71FD6E6'><pre id='7BD71FD6E6'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          leisure time 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          leisure time  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：566
                                  
                                    
          
                                    
          Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC.
          Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. 																									Michelle C. Gevint for STAT
          NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?
          Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.
          advertisement
          Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Goldman Sachs launches $650M fund for life science investments
                                
                            
          Next article：  
                                      
                                          BioMarin wins approval for gene therapy to treat hemophilia A
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          Wikipedia
          
                  
          

                    
          
            
          
              
                Apple is now the first public company to be valued at $3 trillion
                
          
                        
              
          
                Apple is now the first public company to be valued at $3 trillion
                
          
                  
          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO
                
          
                        
              
          
                Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO
                
          
                  
          MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Medical records are filled with copy
                
          
                        
              
          
                Medical records are filled with copy
                
          
                  
          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          Videos point to link between seizures and unexplained toddler deaths
          
            
          KatieCzajkowski-Fellholdingaphotoofherhusband,JustinFell,withtheirtwinsonsCameron(left)andHayden.And
          
          
          
          
          
            read more